Test results of QTempo, ReproCELL’s cardiotoxicity assay using ReproCardio cardiomyocytes

Data obtained by QTempo assay

With QTempo assay, safety pharmacology studies with in vivo ECG-like recordings are possible in vitro. The figures below show the QT prolongation analysis with Astemizole, a potent histamine H1-receptor antagonist withdrawn from market due to QT prolongation. QTempo also allows the quantification of other parameters including beat rate and the effects on numerous kinds of ion channels, not just K+ channels, at the same time.
 
Click the figures to enlarge

Comparison of QTempo and hERG assay

Figure 1 is the comparison of the test results for 8 compounds from QTempo and the published hERG assay reports. In terms of detection of the QT prolongation, QTempo replicated the in vivo results better than hERG assay, the current standard in vitro assay (see the highlighted rows for dl-Sotalol and Verapamil).

Figure 1: Comparison between QTempo & hERG assay for detection of cardiotoxicity
QTempo can be conducted using ReproCardio (human iPSC-cardiomyocytes), human ESC-cardiomyocytes and monkey ESC-cardiomyocytes.
Click the figure to enlarge

Figure 2: Dose-dependency of QT interval measured with QTempo
Click the figure to enlarge

Table 1: Comparison between QTempo & hERG assay in the aspects important for drug development